Workplace safety, public health and procedural fairness dominate the latest DEA marijuana rescheduling hearings as opponents continue to lead testimony.
The federal government’s marijuana rescheduling hearings have entered a pivotal stage, with the past three days focusing less on cannabis itself and more on the broader consequences of changing its federal classification. Rather than hearing from a balanced mix of supporters and opponents, the proceedings have largely featured organizations opposed to moving marijuana from Schedule I to Schedule III, creating ongoing debate about whether the administrative process fairly represents all sides of the issue.
The hearings, being conducted by the Drug Enforcement Administration (DEA), are intended to create the official administrative record which will help determine whether marijuana should be reclassified under the Controlled Substances Act. While the Department of Health and Human Services previously concluded marijuana has accepted medical uses and recommended moving it to Schedule III, the hearing process has become increasingly controversial because nearly all of the outside testimony has come from organizations arguing against the recommendation.
RELATED: Who Is the Same Size As The Cannabis Industry
One of the most closely watched presentations during the past several days came from representatives of the National Drug & Alcohol Screening Association (NDASA). Their testimony centered on workplace safety and employer drug-testing programs, particularly for employees working in transportation, construction, manufacturing, healthcare, and other safety-sensitive occupations.
NDASA representatives argued reducing federal restrictions on marijuana could complicate workplace drug-testing policies and potentially make it more difficult for employers to ensure employees are fit for duty. They expressed concern businesses responsible for public safety could face additional legal and operational challenges if cannabis receives a lower federal classification.
Transportation safety also became a significant topic of discussion. Witnesses argued industries regulated by federal safety standards depend upon consistent drug-testing policies and questioned whether rescheduling could create uncertainty for employers attempting to comply with existing federal regulations. While moving marijuana to Schedule III would not legalize recreational cannabis nationwide, opponents argued the policy change could nevertheless alter public perception regarding workplace marijuana use.
The hearings also continued to feature testimony from prohibition-oriented organizations, including Smart Approaches to Marijuana (SAM), one of the country’s most prominent opponents of cannabis legalization. SAM representatives argued reducing federal restrictions would send the wrong message about marijuana’s health risks and could contribute to increased cannabis use among young adults.
Their testimony focused on concerns involving mental health, addiction, impaired driving, youth access, and the potential long-term public health consequences of expanded marijuana acceptance. Witnesses urged the DEA to maintain marijuana’s current Schedule I status, arguing existing scientific evidence does not justify changing its federal classification.
While these concerns have become central themes of the hearings, they have also highlighted what many observers consider the most unusual aspect of the proceeding: its one-sided structure.
RELATED: The Numbers Show Americans Support Legal Cannabis
Although the DEA is defending the Department of Health and Human Services’ recommendation to reschedule marijuana, nearly all of the private organizations permitted to testify have been opponents of the proposal. Cannabis advocacy organizations, patient groups, licensed cannabis businesses, physicians supporting medical marijuana, and many scientific organizations favoring rescheduling were not granted opportunities to present affirmative testimony during the hearing itself.
Critics argue excluding pro-rescheduling witnesses creates an incomplete administrative record by limiting the diversity of perspectives available to the administrative law judge and the DEA. Supporters of the current format counter the federal government itself serves as the proponent of the proposed rule, making additional supportive witnesses unnecessary under the agency’s procedures.
Regardless of where one stands on marijuana policy, the hearings have demonstrated the debate extends far beyond legalization. Questions surrounding workplace safety, employer liability, transportation regulations, public health, medical research, and federal law all remain central to determining marijuana’s future classification.
The hearings are expected to continue through mid-July before the administrative record is closed. Following the process, the DEA will review the testimony, scientific evidence, and legal arguments before making a final decision on whether marijuana should remain a Schedule I substance or move to Schedule III.
For the cannabis industry, healthcare professionals, employers, researchers, and millions of Americans living in states with legal cannabis, the outcome could shape federal marijuana policy for years to come. While the testimony over the past three days has largely reflected the views of rescheduling opponents, the broader national debate over cannabis remains far more diverse than the hearing room itself.
